We would love to hear your thoughts about our site and services, please take our survey here.
Just topped up
Expect good times this year
Yes -totally agree
RBC target 60p
Expect that to be a minimum
imho dyor
Possitive cash flow so no need for more fundraising
imho - dyor
10.188-10.84
Looking at he possibilities in USA will be the big one though
Soon
9.695-9.88p
Https://www.marketscreener.com/insider/JOSEPH-ERRICO-A1M2IX/
And this is just the beginning
RBC capital target 60p
9.575-9.999p
Jonboi1968 speaks the truth
Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) has appointed Joseph P. ("JP") Errico as Chief Financial Officer.[i] JP will be responsible for managing and developing Ondine's finance function, as well as managing the capital markets interface, participating in discussions with large health systems and customers, and working closely with the management team on overall growth strategy, both from a financial and operational perspective.
JP has successfully founded and sold (or taken public) several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore, with his patented products generating over $20 billion in sales.
Carolyn Cross, CEO and founder of Ondine commented:
"We are delighted that JP has agreed to join Ondine at this exciting time. His experience in finance, capital markets and developing medtech companies will be invaluable as we move forward with our international expansion and achieving FDA approval in conjunction with our partner HCA Healthcare."
JP Errico commented:
"Ondine represents a unique opportunity to create shareholder value while heading off one of humanity's greatest health threats, antimicrobial resistance. I am proud to be joining an excellent team of professionals as Ondine brings this critically needed technology to the world."
JP's educational background includes an undergraduate degree in Aeronautical Engineering from the Massachusetts Institute of Technology and graduate degrees in both Law and Mechanical/Materials Engineering from Duke University. He is also a trained patent attorney.
9.10-9.49p
Starting to make its move
Ondine Biomedical Inc - Vancouver-based life sciences company - Appoints Joseph Errico as chief financial officer, though doesn't provide start date. Says Errico has successfully founded, sold, or taken public several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore.
Chief Executive Officer Carolyn Cross says: "We are delighted that JP has agreed to join Ondine at this exciting time. His experience in finance, capital markets and developing medtech companies will be invaluable as we move forward with our international expansion and achieving FDA approval in conjunction with our partner HCA Healthcare."
Cross said the fact that many hospitals were recommending Steriwave to other hospitals was "particularly encouraging".
"We believe this momentum will continue to increase, and commercial sales will become more significant in 2024."
Efforts to be a commercial success
currently achieving break-even or better
in my view but do you own research
Mark my words
dyor - imo
Chief Executive Officer Carolyn Cross commented: "It is hugely satisfying that Steriwave is now available in hospitals from coast to coast across Canada, giving patients enhanced protection against post-surgical infections. This new hospital deployment demonstrates Steriwave's growing status as an effective alternative to topical antibiotics for infection prevention that easily fits into existing hospital workflows."
4.10-4.359
Public opinion